An observational study in Opiod Use Disorder, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 22 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by University of Illinois at Chicago · Observational
The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.
We will recruit up to 130 subjects for this study, with the intention of enrolling 50 OUD subjects at various stages of treatment and 20 age-matched non-OUD controls.
Eligible subjects will contact or give verbal permission to be contacted via their referring provider, by a co-investigator to obtain more information about the study. At the first point of contact (usually a phone call), study co- investigator will administer a phone-screening questionnaire. Once the phone screening process is complete, the information gathered by the co-investigator will be taken to the PI of the study for further review to confirm eligibility. Data obtained from screening will be safely stored in the PI's locked office.
Informed consent will be obtained by the study PI and/or a co-investigator (not involved in the patient's care) in person. The test procedures will be described and the testing equipment will be shown to the subject. Study co-investigators will clearly explain all the procedures and risks of the testing outlined in the consent form. The subject will be given the time needed to consider their decision and will be encouraged to ask questions, both during the initial phone interview and throughout the study. The PI or a co-investigator will answer any questions regarding the study at the time consent is given. Once enrolled, the subject may pause or terminate his/her participation at any time during the study.
Procedures Involved* This is an observational study that includes an EEG at rest and also an EEG conducted while the subject is simultaneously completing a computer assessment. The study will have 50 OUD patients and 20 age-matched controls. Subjects will undergo EEG testing in addition to testing done concurrently with computer assessments. An additional visit will be conducted around 1 week after the initial visit. Additionally, subjects will undergo questionnaires/assessments regarding demographics, HPI, craving, mood, impulsivity, and drug use. Urine toxicology and Hair follicle (when available) will also be conducted.
1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's planned enrollment of 70 is below the median of 129 across 174 observational studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →University of Illinois at Chicago is the lead sponsor of 515 studies on the registry; 133 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults aged 22-85 years who live locally and consent will be enrolled in two groups: an OUD cohort (DSM-5 opioid use disorder ≥6 months, positive urine toxicology, ongoing craving) and an age-matched non-OUD control group. All must reside in the study area with no relocation plans. Exclusion criteria (both cohorts) include recent antiepileptic initiation; history of stroke, brain tumor, epilepsy, unexplained syncope, significant head injury with loss of consciousness, or brain surgery; severe depression; active malignancy; and, for OUD subjects, recent ingestion of poppy seeds or Papaveris fructus products.
For OUD Subjects:
Having a diagnosis of OUD
4. Lives in immediate area with no plans to relocate.
For age-matched controls:
Exclusion Criteria:
For OUD Subjects:
For age-matched controls:
Diagnosed Opioid Use Disorder subjects will perform 2 EEG sessions done at the initial visit and one week later. EEG recordings will be taken to monitor brain activity
Age-matched healthy controls. Subjects will perform 2 EEG sessions done at the initial visit and one week later. EEG recordings will be taken to monitor brain activity
Electroencephalogram power in Delta through Gamma bands
High-density electroencephalogram power will be assessed during rest (eyes open, eyes closed) and activity
Time frame: 1 week
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago